1. Once-weekly semaglutide significantly increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes.
2. In this Danish cohort study of more than 400,000 patients with type 2 diabetes, semaglutide users exhibited a 2.19-fold increased risk of NAION.
3. The median time from first semaglutide prescription to NAION diagnosis was 22.2 months.
4. Findings suggest the need for further studies to identify high-risk subgroups.

Source: International Journal of Retina and Vitreous